Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035056 | 0.90 | CTSK (0.39) | CTSKCTSLCTSSCACNA1B | |
| SCHEMBL7032706 | 0.84 | CTSK (0.36) | CTSKCTSLCTSSCACNA1B | |
| SCHEMBL7033232 | 0.83 | METAP2 (0.34) | CTSKCTSS | |
| SCHEMBL7036267 | 0.82 | METAP2 (0.35) | CTSS | |
| SCHEMBL6475371 | 0.77 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL6475375 | 0.77 | CTSK (0.54) | CTSKCTSLCTSS | |
| SCHEMBL6487199 | 0.75 | CTSK (0.51) | CTSKCTSLCTSS | |
| SCHEMBL7039308 | 0.73 | METAP2 (0.33) | CTSKCTSLCTSS | |
| SCHEMBL6475776 | 0.73 | CTSK (0.49) | CTSKCTSLCTSS | |
| SCHEMBL6475769 | 0.73 | CTSK (0.49) | CTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | claimed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSK 4/4885CTSL 11/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.